These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23828743)

  • 21. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis.
    O'Hare JD; Zielinski E; Cheng B; Scherer T; Buettner C
    Diabetes; 2011 Apr; 60(4):1055-62. PubMed ID: 21447652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Liver Fatty Acid Binding Protein-1 T94A Variant, Nonalcohol Fatty Liver Disease, and Hepatic Endocannabinoid System.
    Martin GG; Landrock D; Dangott LJ; McIntosh AL; Kier AB; Schroeder F
    Lipids; 2018 Jan; 53(1):27-40. PubMed ID: 29488637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade.
    Engeli S
    Obes Facts; 2008; 1(1):8-15. PubMed ID: 20054157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of an Orally Bioavailable, Brain-Penetrant Compound with Selectivity for the Cannabinoid Type 2 Receptor.
    Ospanov M; Sulochana SP; Paris JJ; Rimoldi JM; Ashpole N; Walker L; Ross SA; Shilabin AG; Ibrahim MA
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: the endocannabinoid system in liver disease, a potential therapeutic target.
    Basu PP; Aloysius MM; Shah NJ; Brown RS
    Aliment Pharmacol Ther; 2014 Apr; 39(8):790-801. PubMed ID: 24612021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.
    Osafo N; Yeboah OK; Antwi AO
    Mol Biol Rep; 2021 Apr; 48(4):3665-3680. PubMed ID: 33909195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.
    Mallat A; Teixeira-Clerc F; Deveaux V; Manin S; Lotersztajn S
    Br J Pharmacol; 2011 Aug; 163(7):1432-40. PubMed ID: 21457226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of cannabinoids in the development of fatty liver (steatosis).
    Purohit V; Rapaka R; Shurtleff D
    AAPS J; 2010 Jun; 12(2):233-7. PubMed ID: 20204561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?
    Schulz P; Hryhorowicz S; Rychter AM; Zawada A; Słomski R; Dobrowolska A; Krela-Kaźmierczak I
    Nutrients; 2021 Jan; 13(2):. PubMed ID: 33530406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.
    Jeong WI; Osei-Hyiaman D; Park O; Liu J; Bátkai S; Mukhopadhyay P; Horiguchi N; Harvey-White J; Marsicano G; Lutz B; Gao B; Kunos G
    Cell Metab; 2008 Mar; 7(3):227-35. PubMed ID: 18316028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of lipids and lipid signaling in the development of cannabinoid tolerance.
    Martin BR
    Life Sci; 2005 Aug; 77(14):1543-58. PubMed ID: 15949820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.
    Richey JM; Woolcott O
    Curr Diab Rep; 2017 Sep; 17(10):99. PubMed ID: 28913816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral modulation of the endocannabinoid system in metabolic disease.
    Shrestha N; Cuffe JSM; Hutchinson DS; Headrick JP; Perkins AV; McAinch AJ; Hryciw DH
    Drug Discov Today; 2018 Mar; 23(3):592-604. PubMed ID: 29331500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.
    Argenziano M; Tortora C; Bellini G; Di Paola A; Punzo F; Rossi F
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of CB1 Antagonism on Hepatic Oxidative/Nitrosative Stress and Inflammation in Nonalcoholic Fatty Liver Disease.
    Jorgačević B; Vučević D; Samardžić J; Mladenović D; Vesković M; Vukićević D; Ješić R; Radosavljević T
    Curr Med Chem; 2021; 28(1):169-180. PubMed ID: 32124686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.
    Shi D; Zhan X; Yu X; Jia M; Zhang Y; Yao J; Hu X; Bao Z
    Lipids Health Dis; 2014 Nov; 13():173. PubMed ID: 25406988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.